Clinical trials: B Lymphoblastic Leukemia
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004040
- Testing
- recombinant interferon alfa, rituximab
- Where
- 3 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL), Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This is a single-arm, open-label, phase I study (safety and dose escalation) of autologous Chimeric Antigen Receptor (CAR) T-cells targeting CD19 in patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL).
- Trial name
- NCT04653493
- Testing
- CD19 CAR engineered autologous T-cells, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Iran
- Volunteers
- 22 people
- Sponsor
- Sabz Biomedicals
B-cell Acute Lymphoblastic Leukemia
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main method potentially curing adult B-ALL, but the high treatment-related mortality (NRM) affects overall survival (OS).
- Trial name
- NCT06507514
- Testing
- blinatumomab and auto-HSCT "sandwich " strategy
- Where
- China
- Volunteers
- 4 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed/Refractory Pediatric B-ALL
JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL
This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia to evaluate the safety and efficacy of…
- Trial name
- NCT07406178
- Testing
- JY509 universal NK cell injection
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.
- Trial name
- NCT04226989
- Testing
- CT-RD06
- Where
- China
- Volunteers
- 72 people
- Sponsor
- He Huang
Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
This clinical trial is looking at brain function in young patients receiving methotrexate for acute lymphoblastic leukemia. Learning about the long-term effects of methotrexate on brain function may help doctors plan cancer…
- Conditions
- Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Cognitive Side Effects of Cancer Therapy, Long-Term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00437060
- Testing
- Cognitive Assessment, Diffusion Tensor Imaging, Laboratory Biomarker Analysis
- Where
- 112 sites in United States, Australia and 2 more
- Volunteers
- 233 people
- Sponsor
- Children's Oncology Group
Bone Marrow Transplant (BMT)
HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons.
- Trial name
- HOPE (NCT07145411)
- Testing
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ossium Health, Inc.
Lymphoma
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003650
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- France
- Volunteers
- 179 people
- Sponsor
- UNICANCER
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Allo HSCT Using RIC for Hematological Diseases
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia
- Trial name
- NCT02661035
- Testing
- Allopurinol, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory…
- Trial name
- NCT06173518
- Testing
- AUTO1
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Autolus Limited
Leukemia, Lymphoma
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006220
- Testing
- arsenic trioxide, tretinoin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine